SDS-PAGE
(Purity: Sample purity data. for lot-specific data, please refer to the respective data)
COVID 19 Spike RBD (Y449H, E484K, N501Y) Coronavirus Recombinant Protein | COVID-19 recombinant protein
2019-nCoV Spike protein RBD (Y449H, E484K, N501Y)
Synonyms
COVID 19 Spike RBD (Y449H, E484K, N501Y) Coronavirus; N/A; 2019-nCoV Spike protein RBD (Y449H, E484K, N501Y); 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike RBD (Y449H, E484K, N501Y); 2019-nCoV RBD; SARS-CoV-2 spike RBD; novel coronavirus spike RBD; nCoV spike RBD; SARS-CoV-2 variant C.1.2.; COVID-19 recombinant protein
Host
CHO cells
Form/Format
Recombinant protein stored in 50mM sodium phosphate, pH7.5, 300mM NaCl, 150mM imidazole.
Concentration
1.0ug/ul (varies by lot)
Tag
HIS
Species
Human
Dry Ice Shipment
Extra charge fee may add to your shipping cost as dry ice is required to ship this product.
Preparation and Storage
Store product at -70 degree C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
SDS-PAGE
(Purity: Sample purity data. for lot-specific data, please refer to the respective data)
SDS-PAGE
(Purity: Sample purity data. for lot-specific data, please refer to the respective data)
Activity
(Activity: Sample activity data. For lot specific data please refer to the specific datasheet.)
Activity
(Activity: Sample activity data. For lot specific data please refer to the specific datasheet.)
Related Product Information for COVID-19 recombinant protein
Recombinant 2019-nCoV Spike protein S1 subunit, RBD (Y449H, E484K, N501Y) was expressed in CHO cells using a C-terminal his tag. The gene accession number is MN908947.
The receptor binding domain (RBD) of SARS-CoV-2 spike glycoprotein can recognize the ACE2 receptor of the host and is an important determining factor of viral entry and neutralization (1). The SARS-CoV-2 variant C.1.2 carries the mutations Y449H, E484K, and N501Y on its RBD and these mutations together manifest resistance to antiviral immunity. Virus with C.1.2 spike is more resistant to antibody neutralization than any variants of concern (VOCs)(2). As more virus emerge, it is pivotal to study the transmissibility, virulence, and their possible tendency to escape antibody neutralization of the virus (3).
The receptor binding domain (RBD) of SARS-CoV-2 spike glycoprotein can recognize the ACE2 receptor of the host and is an important determining factor of viral entry and neutralization (1). The SARS-CoV-2 variant C.1.2 carries the mutations Y449H, E484K, and N501Y on its RBD and these mutations together manifest resistance to antiviral immunity. Virus with C.1.2 spike is more resistant to antibody neutralization than any variants of concern (VOCs)(2). As more virus emerge, it is pivotal to study the transmissibility, virulence, and their possible tendency to escape antibody neutralization of the virus (3).
Product Categories/Family for COVID-19 recombinant protein
References
1. Lan J, et al: Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor. bioRxiv. doi: https://doi.org/10.1101/2020.02.19.956235
2. Tada T, et al: Neutralization of Mu and C. 1.2 SARS-CoV-2 Variants by Vaccine-elicited Antibodies in Individuals With and Without Previous History of Infection. bioRxiv. doi: https://doi.org/10.1101/2021.10.19.463727
3. Starr TN, et al: Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417T and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant. Cell. 2020, 182(5):1295-1310.
2. Tada T, et al: Neutralization of Mu and C. 1.2 SARS-CoV-2 Variants by Vaccine-elicited Antibodies in Individuals With and Without Previous History of Infection. bioRxiv. doi: https://doi.org/10.1101/2021.10.19.463727
3. Starr TN, et al: Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417T and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant. Cell. 2020, 182(5):1295-1310.
NCBI and Uniprot Product Information
Similar Products
Product Notes
The COVID-19 (Catalog #AAA73343) is a Recombinant Protein produced from CHO cells and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "COVID 19 Spike RBD (Y449H, E484K, N501Y) Coronavirus, Recombinant Protein" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.